Login / Signup

Metabolic syndrome biomarkers relate to rate of cognitive decline in MCI and dementia stages of Alzheimer's disease.

Jagan A PillaiJames BenaLynn BekrisNandan KodurTakhar KasumovJames B LeverenzSangeeta R Kashyapnull null
Published in: Alzheimer's research & therapy (2023)
Biomarkers of metabolic syndrome relate to rate of cognitive decline among MCI and dementia individuals. Elevated plasma TG/HDL-C ratio and plasma ApoA1 are associated with worse cognitive outcomes in MCI and dementia participants. CSF ApoA1 and plasma ApoA1 likely have different roles in AD progression in MCI stage.
Keyphrases
  • mild cognitive impairment
  • cognitive decline
  • metabolic syndrome
  • insulin resistance
  • uric acid
  • cardiovascular disease
  • cardiovascular risk factors
  • adipose tissue
  • glycemic control